alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 20,201–20,225 of 27,146 studies marked Peer-reviewed (page 809 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists 2005-06-01

The present study explored several different procedures for determining the amount of change that occurred on the Mini-Mental State Exam [MMSE; Folstein, M. (1975). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

PET studies in dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Annals of nuclear medicine 2003-04-01

Measurement of local cerebral glucose metabolism (lCMRGlc) by positron emission tomography (PET) and 18F-2-fluoro-2-deoxy-D-glucose (FDG) has become a standard technique during the past 20 years and is now available at many university hospitals in all highly developed countries. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Diagnostic accuracy of mini-mental status examination and revised hasegawa dementia scale for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Dementia and geriatric cognitive disorders 2005-03-22

To compare the diagnostic accuracies of the Revised Hasegawa Dementia Scale (HDS-R) and Mini-Mental Status Examination (MMSE) for Alzheimer's diseases (AD), we administered them simultaneously to 82 AD patients and 82 age- and sex-matched nondemented control subjects. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Hepatic encephalopathy: An update of pathophysiologic mechanisms

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1999-11-01

Hepatic encephalopathy (HE) is a neuropsychiatric disorder that occurs in both acute and chronic liver failure. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Current pharmaceutical design 2016-01-01

Alzheimer's disease (AD), the most common form of dementia, is a progressive disorder manifested by gradual memory loss and subsequent impairment in mental and behavioral functions. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Protective effects of estrogen and selective estrogen receptor modulators in the brain

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Biology of reproduction 2002-11-01

Within the last few years, there has been a growing interest in the neuroprotective effects of estrogen and the possible beneficial effects of estrogen in neurodegenerative diseases such as stroke, Alzheimer disease, and Parkinson disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The American journal of pathology 1997-10-01

Entry of the type 1 human immunodeficiency virus into most cells requires the presence of the CD4 protein in combination with one of several recently described co-receptors. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Expert reviews in molecular medicine 2011-06-10

Diseases of the central nervous system (CNS) pose a significant health challenge, but despite their diversity, they share many common features and mechanisms. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The role of built and social environments in Alzheimer's disease dementia prevalence in the United States: A machine learning approach

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Alzheimer s Disease 2025-09-01

Significant regional differences in AD dementia prevalence were observed (F = 126.56, p < 0.05). 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Antipsychotic prescribing patterns in a Medicare Advantage population of older individuals with dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Mental Health 2016-11-12

Of the 8688 individuals in the Medicare Advantage population with a dementia diagnosis, 1061 (12.2%) received an antipsychotic medication. 4 key findings →

Participants: 8,688 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

After Risk-Adjustment Change, Dementia Diagnoses Increased In Medicare Advantage Relative To Traditional Medicare

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Health Affairs 2025-01-01

In 2020, the Centers for Medicare and Medicaid Services reintroduced Alzheimer's disease and related dementias to its risk-adjustment payment model for Medicare Advantage (MA) plans. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of medication adherence quality measures for diabetes, hypertension, and hyperlipidemia with cognitive decline

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Family Medicine and Primary Care 2023-11-01

The study population of 99,774 individuals had a mean age of 71.0 years and was 49.1% female, 73.9% White, and 17.8% Black, with 62.0% living in an urban setting. 5 key findings →

Participants: 99,774 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The impact of the implementation of a national policy on dementia on healthcare costs in older patients with dementia in Korea: a quasi-experimental difference-in-difference study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet Regional Health - Western Pacific 2024-01-27

Policy implementation was associated with a significant decrease in patient out-of-pocket cost. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Performance of Claims-based Dementia Algorithms in Medicare Fee-for-service and Medicare Advantage Populations

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Innovation in Aging 2025-12-01

Claims-based dementia algorithms have not been evaluated in the Medicare Advantage (MA) population, a critical gap given the rapid growth of MA and concerns about data completeness. 3 key findings →

Participants: 5,058 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Evaluation of Telehealth's Impact on Medicare Annual Wellness Visits and Dementia Diagnosis

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

We found a significant increase in the likelihood of AWV uptake among telehealth adopters by 10.2 percentage points (p <0.001) than non-adopters of telehealth in traditional FFS Medicare plans. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed